Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D009196 | Myeloproliferative Disorders NIH | 1.00 |
| D054437 | Myelodysplastic-Myeloproliferative Diseases NIH | 0.58 |
| D007951 | Leukemia, Myeloid, NIH | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0012324 | Myeloid leukemia HPO | 0.41 |
| HP:0002863 | Myelodysplasia HPO | 0.33 |
| HP:0004808 | Acute myeloid leukemia HPO | 0.33 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002664 | Neoplasm HPO | 0.17 |
| HP:0001909 | Leukemia HPO | 0.14 |
Navigate: Correlations HPO
There are 3 clinical trials
An increased risk of both venous and arterial thromboembolism was noted in reports from SARS-CoV-2-infected patients in China and has been confirmed in autopsy findings from patients who experienced sudden death. Myeloproliferative Neoplasms (MPNs), which encompass polycythemia vera, essential thrombocythemia and primary myelofibrosis, are thrombophilic disorders with a natural propensity to thrombosis that is fuelled by the intrinsic activation of inflammatory cytokines. It therefore follows that an underlying diagnosis of MPN may increase the risk of worse clinical outcomes and death during periods of active Covid-19 disease. This ambispective, observational study aims to elucidate the key factors which affect the clinical course of patients with MPN who develop Covid-19 disease.
Description: Incidence of cases of MPN patients with COVID-19 experiencing pulmonary embolism
Measure: pulmonary embolism (PE) Time: 2 and a half monthsDescription: Incidence of cases reporting at least one fatal or non fatal thrombotic event reported in therapy of MPN
Measure: fatal or non fatal thrombotic event Time: 2 and a half monthsDescription: Incidence of cases reporting at least one COVID-19 worsening outcome as Continuous Positive Airway Pressure (CPAP)
Measure: Continuous Positive Airway Pressure (CPAP) Time: 2 and a half monthsDescription: Incidence of cases reporting at least one COVID-19 worsening outcome as invasive ventilation
Measure: invasive ventilation Time: 2 and a half monthsDescription: Incidence of cases reporting at least one COVID-19 worsening outcome as Intensive Care Unit (ICU)
Measure: admission in Intensive Care Unit (ICU) Time: 2 and a half monthsDescription: incidence of death
Measure: death Time: 2 and a half monthsDescription: Type of treatments and interventions applied for MPN during COVID-19 and any change reported in therapy of MPN
Measure: treatments and interventions applied for MPN Time: 2 and a half monthsDescription: Type of treatments and interventions applied for COVID-19
Measure: treatments and interventions applied for COVID-19 Time: 2 and a half monthsDescription: Odds Ratios (ORs) of the outcome and 95% Confidence Intervals (CIs) associated with patients' characteristics and treatments
Measure: thrombotic events association to patients characteristic and treatments Time: 2 and a half monthsThe classic myeloproliferative neoplasias (MNP), including polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) or secondary to PV or ET, are among the most frequent of malignant hemopathies, with overall prevalence estimated at around 10,000 patients followed in France. Due to the median age of patients around 65, the frequency of cardiovascular complications of these thrombogenic diseases and the impact of cytoreductive treatments on immune cells, these patients are considered to be at risk of developing forms severe of COVID-19. This study will assess the impact of MNPs on the risk of developing a severe form of COVID-19, identify new risk factors linked to the disease as well as the impact of treatments for MNPs according to their pharmacological class.
Description: The crude rate of cumulative incidence of serious infection proven to COVID-19, compared to the population of the same age, same sex, same region of residence during the epidemic period.
Measure: Rate of serious coronavirus infection in different MNP patient subgroups Time: Through inclusion period, an average of 6 monthsDescription: Number of MNP patients who had COVID-19 compared to general population in France
Measure: Proportion of MNP patients who had COVID-19 infection during the 2020 epidemic. Time: Through inclusion period, an average of 6 monthsDescription: Number of MNP patients who died from COVID-19
Measure: Rate of death of MNP patients who had COVID-19 Time: Through study completion, an average of 1 yearDescription: Number of MNP patients hospitalized in intensive care with need for mechanical ventilation
Measure: Rate of passages in intensive care with need for mechanical ventilation Time: Through study completion, an average of 1 yearThis is research study to find out if a drug called ADCT-301 is safe and to look at how patients respond to the study drug after an allogeneic transplantation. ADCT-301 will be administered on Days 1, 8 and 15 with blood tests following study drug infusion. Patients will have a bone marrow biopsy at the end of cycle 2/before cycle 3 to see how they are responding to the study drug. Patients will be followed for approximately every 12 weeks from the last disease assessment for up to 1 year from completion of therapy. There are risks to this study drug. Some risks include: decrease in certain blood cells, weight loss, loss of appetite, rash and Guillain-Barre syndrome, where the immune system attacks and damages nerves.
Description: Investigator report; efficacy rule
Measure: Morphologic complete response rate of ADCT-301 Time: End of Study, up to 3 yearsDescription: Number of adverse events as measured by self report
Measure: Safety of ADCT-301 Time: up to 12 weeks (84 days) after the last doseAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports